14th Annual Meeting of the Psychoneuroimmunology Research Society

• VAN DER KOOY K, VAN HOUT H, MARWIJK H et al.: Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int. J. Geriatr. Psychiatry (2007) 22:613-626.
   PubMed Web of Science ®Google Scholar
• SHEEHY C, MURPHY E, BARRY M: Depression in rheumatoid arthritis – underscoring the problem. Rheumatology (2006) 45:1325-1327.
   PubMed Web of Science ®Google Scholar
• PALKONAYI E, KOLARZ G, KOPP M et al.: Depressive symptoms in early rheumatoid arthritis. Clin. Rheumatol. (2007) 26:753-758.
   PubMed Web of Science ®Google Scholar
• RICKARDS H: Depression in neurological disorders: an update. Curr. Opin. Psychiatry (2006) 19:294-298.
   PubMed Web of Science ®Google Scholar
• LEONARD BE, MYINT A: Inflammation and depression: is there a causal connection with dementia? Neurotox. Res. (2006) 10:149-160.
   PubMed Web of Science ®Google Scholar
• BURGUT FT, BENAUR M, HENCLIFFE C: Late-life depression: a neuropsychiatric approach. Exp. Rev. Neurother. (2006) 6:65-72.
   PubMed Web of Science ®Google Scholar
• HAYLEY S, ANISMAN H: Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates. Curr. Pharmaceut. Design (2005) 11:947-962.
   PubMed Web of Science ®Google Scholar
• GODBOUT JP, JOHNSON RW: Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Neurol. Clin. (2006) 24:521-538.
   PubMed Web of Science ®Google Scholar
• DONOVAN KA, JACOBSEN PB: Fatigue, depression and insomnia: evidence for a symptom cluster in cancer. Semin. Oncol. Nurs. (2007) 23:127-135.
   PubMedGoogle Scholar
• FISCH M: Use of antidepressants for depression in patients with advanced cancer. Lancet Oncol. (2007) 8:567-568.
   PubMed Web of Science ®Google Scholar
• PANDEY M, GANGADHARAN PD, NANDKUMAR T et al.: Distress, anxiety and depression in cancer patients undergoing chemotherapy. World J. Surg. Oncol. (2006) 4:68.
   PubMedGoogle Scholar
• DANTZER R, KELLEY KW: Twenty years of research on cytokine-induced sickness behavious. Brain Behav. Immun. (2007) 21:153-160.
   PubMed Web of Science ®Google Scholar
• RIEF W, PILGER F, IHLE D et al.: Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. (2001) 105:165-174.
   PubMed Web of Science ®Google Scholar
• ANISMAN H, MERALI Z: Cytokines, stress and depressive illness. Brain Behav. Immun. (2002) 16:513-524.
   PubMed Web of Science ®Google Scholar
• ANISMAN H, MERALI Z, POULTER MO, HAYLEY: Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharmaceut. Design (2005) 11:963-972.
   PubMed Web of Science ®Google Scholar
• HAYLEY S, POULTER MO, MERALI Z, ANISMAN H: The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience (2005) 135:659-678.
   PubMed Web of Science ®Google Scholar
• VOLLMER-CONNA U, FAZOU C, CAMERON B et al.: Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol. Med. (2004) 34:1289-1297.
   PubMed Web of Science ®Google Scholar
• DANTZER R: Cytokine, sickness behaviour and depression. Neurol. Clin. (2006) 24:441-460.
   PubMed Web of Science ®Google Scholar
• DANTZER R: Somatization: a psychoneurimmune perspective. Psychoneuroendocrinology (2005) 30:947-952.
   PubMed Web of Science ®Google Scholar
• ASNIS GM, DE LA GARZA R: Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. J. Clin. Gastroenterol. (2006) 40:322-335.
   PubMed Web of Science ®Google Scholar
• RAISON CL, CAPURON L, MILLER AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. (2006) 27:24-31.
   PubMed Web of Science ®Google Scholar
• CAPURON L, GUMNICK JF, MUSSELMAN DL et al.: Neurobehavioural effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 26:643-652.
   PubMed Web of Science ®Google Scholar
• DELL'OSSO L, PINI S, MAGGI L et al.: Subthreshold mania as a predictor of depression during interferon treatment in HCV+ patients without current lifetime psychiatric disorders. J. Psycho. Res. (2007) 62:349-355.
   Google Scholar
• CAPURON L, MILLER AH: Cytokines and psychopathology: lessons from interferon-a. Biol. Psychiatry (2004) 56:819-824.
   PubMed Web of Science ®Google Scholar
• CAPURON L, NEURATER G, MUSSELMAN DL et al.: Interferon-a-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry (2003) 54:906-914.
   PubMed Web of Science ®Google Scholar
• CAPURON L, HAUSER P, HINZE-SELCH D, MILLER AH, NEVEU PJ: Treatment of cytokine-induced depression. Brain Behav. Immun. (2002) 16:575-580.
   PubMed Web of Science ®Google Scholar
• CAPURON L, RAISON CL, MUSSELMAN DL et al.: Association of exaggerated HPA axis response to the initial injection of interferon-a with development of depression during interferon-a therapy. Am. J. Psychiatry (2003) 7:1342-1345.
   Google Scholar
• BRAGULAT V, PAILLERE-MARTINOT ML, ARTIGES E et al.: Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res. (2007) 154:115-124.
   PubMed Web of Science ®Google Scholar
• NOYES R, CARNEY CP, HILLIS SL, JONES LE, LANGBEHN DR: Prevalence and correlates of illness worry in the general population. Psychosomatics (2005) 46:529-539.
   PubMed Web of Science ®Google Scholar
• NOYES R, STUART S, WATSON DB, LANGBEHN DR: Distinguishing between hypochondriasis and somatization disorder: a review of the existing literature. Psychother. Psychosom. (2006) 75:270-281.
   PubMed Web of Science ®Google Scholar
• FINK P, HANSEN MS, SONDERGAARD L: Somatoform disorders among first-time referrals to a neurology service. Psychosomatics (2005) 46:540-548.
   PubMed Web of Science ®Google Scholar
• SCHUBERT C, HONG S, NATARAJAN L, MILS PJ, DIMSDALE JE: The association between fatigue ad inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. (2007) 21:413-427.
   PubMed Web of Science ®Google Scholar
• HONG S, BARDWELL WA, NATARAJAN L et al.: Correlates of physical activity level in breast cancer survivors participating in the women's healthy eating and living (WHEL) study. Breast Cancer Res. Treat. (2007) 101:225-232.
   PubMed Web of Science ®Google Scholar
• FISHER JP: Comments. Br. Med. J. (1995) 310:70.
   Google Scholar
• USA Today article 16/1/05.
   Google Scholar
• MOSKOWITZ DS, YOUNG SN: Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology. J. Psychiatry Neurosci. (2006) 31:13-20.
   PubMed Web of Science ®Google Scholar
• HUSKY MM, GRONDIN OS, SWENDSEN JD: The relation between social behaviour and negative affect in psychosis-prone individuals: an experience sampling investigation. Eur. Psychiatry (2004) 19:1-7.
   PubMed Web of Science ®Google Scholar
• BOWER JE, GANZ PA, AZIZ N, FAHEY JL, COLE SW: T-cell homeostasis in breast cancer survivors with persistent fatigue. J. Natl. Cancer Inst. (2003) 95:1165-1168.
   PubMed Web of Science ®Google Scholar
• COLLADO-HIDALGO A, BOWER JE, GANZ P, COLE SW, IRWIN MR: Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. (2006) 12:2759-2766.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JB, YE Q, HITCHENS TK, KAUFMAN CL, HO C: MRI detection of macrophages labelled using micrometer-sized iron oxide particles. J. Magn. Reson. Imaging (2007) 25:1210-1218.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ O, FRICKE S, CHIEN C et al.: Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle (2006) 5:113-119.
   PubMed Web of Science ®Google Scholar
• VALABLE S, BARBIER EL, BERNAUDIN M et al.: In vivo MRI tracking of exogenous monocytes macrophages targeting brain tumours in a rat model of glioma. Neuroimage (2007) 37(Suppl. 1):S47-S58.
   PubMed Web of Science ®Google Scholar
• DHEEN ST, KAUR C, LING E-A: Microglial activation and its implication in the brain diseases Curr. Med. Chem. (2007) 14:1189-1197.
   PubMed Web of Science ®Google Scholar
• EDISON P, ARCHER HA, HINZ R et al.: Amyloid, hypometabolism and cognition in Alzheimer's disease. An [11C] PIB and [18F] FDG PET study. Neurology (2007) 68:501-508.
   PubMed Web of Science ®Google Scholar
• GERHARD A, PAVESE N, HOTTON G et al.: In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. (2006) 21:404-414.
   PubMed Web of Science ®Google Scholar
• TAI YF, PAVESE N, GERGARD A et al.: Imaging microglial activation in Huntington's disease. Brain Res. Bull. (2007) 72:148-151.
   PubMed Web of Science ®Google Scholar
• PAVESE N, GERHARD A, TAI YF et al.: Microglial activation correlates with severity in Huntington's disease. Neurology (2006) 66:1638-1643.
   PubMed Web of Science ®Google Scholar
• BYE N, HABGOOD MD, CALLAWAY JK et al.: Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp. Neurol. (2007) 204:220-233.
   PubMed Web of Science ®Google Scholar
• TIKKA T, FIEBICH BL, GOLDSTEINS G et al.: Minocylcine, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. (2001) 21:2580-2588.
   PubMed Web of Science ®Google Scholar
• YKI-HARVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 351:1106-1118.
   PubMed Web of Science ®Google Scholar
• BERNARDO A, MINGHETTI L: PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr. Pharmaceut. Design (2006) 12:93-109.
   PubMed Web of Science ®Google Scholar
• BELFIELD GP, DELANEY SJ: Recombinant DNA technology for the 21st century: the impact of molecular biology on drug discovery. Biochem. Soc. Trans. (2006) 34:313-316.
   PubMed Web of Science ®Google Scholar
• CHENG X-R, ZHOU W-X, ZHANG Y-X et al.: Differential gene expression profiles in the hippocampus of senescence-accelerated mouse. Neurobiol. Aging (2007) 28:497-506.
   PubMed Web of Science ®Google Scholar
• RENSINK AAM, OTTE-HOLLER I, TEN DONKELAAR HJ et al.: Differential gene expression in human brain pericytes induced by amyloid-β protein. Neuropathol. Appl. Neurobiol. (2004) 30:279-291.
   PubMed Web of Science ®Google Scholar
• SATTERTHWAITE G, FRANCIS SF, SUVARNA K et al.: Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am. Heart J. (2005) 150:488-499.
   PubMed Web of Science ®Google Scholar
• DAVIES MR, HARDING CJ, RAINES S et al.: Nurr1 dependent regulation of pro-inflammatory mediators in immortalised synovial fibroblasts. J. Inflamm. (2005) 2:1-8.
   Google Scholar
• BRADDOCK M: Wound repair in skin and bone. Sci. Med. (2002) 8:218-229.
   Google Scholar
• BRYANT M, DREW GM, HOUSTON P et al.: Tissue repair with a therapeutic transcription factor. Hum. Gene Ther. (2000) 11:2143-2158.
   PubMed Web of Science ®Google Scholar
• TKALCEVIC VI, CUZIC S, BRAJSA K et al.: Enhancement by PL14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur. J. Pharmacol. (2007) 570(1-3):212-221.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS, ALVARO-GARCIA JM, MAKI R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. (1990) 144:3347-3353.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, BRENNAN FM, FOXWELL BM, TAYLOR PC, WILLIAMS RO, MAINI RN: Anti-TNF therapy: where have we got to in (2005)? J. Autoimmun. (2005) 25:26-28.
   PubMed Web of Science ®Google Scholar
• RANKINE EL, HUGHES PM, BOTHAM MS, PERRY VH, FELTON LM: Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. Eur. J. Neurosci. (2006) 24:77-86.
   PubMed Web of Science ®Google Scholar
• QIN L, WU X, BLOCK ML et al.: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 55:453-462.
   PubMed Web of Science ®Google Scholar
• QIN L, BLOCK ML, LIU Y et al.: Micoglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J. (2005) 19:550-557.
   PubMed Web of Science ®Google Scholar
• QIN L, LIU Y, QIAN X, HONG J-S, BLOCK ML: Microglial NADPH oxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann. NY Acad. Sci. (2005) 1053:107-120.
   PubMed Web of Science ®Google Scholar
• BLOCK ML, HONG J-S: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. (2005) 76:77-98.
   PubMed Web of Science ®Google Scholar
• BLOCK ML, ZECCA L, HONG J-S: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. (2007) 8:57-69.
   PubMed Web of Science ®Google Scholar
• TYRING S, GOTTLIEB A, PAPP K et al.: Etanercept and clinical outcomes, fatigue and depression in psoriasis: double-blind placebo-controlled randomised Phase III trial. Lancet (2006) 367:29-35.
   PubMed Web of Science ®Google Scholar
• MONK JP, PHILLIPS G, WAITE R et al.: Assessment of TNF-a blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. (2006) 24:1852-1859.
   PubMed Web of Science ®Google Scholar
• MULLER N, SCHWARZ MJ, DEHNING S et al.: The cycooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double blind, randomised, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry (2006) 11:680-684.
   PubMed Web of Science ®Google Scholar
• QIAN L, BLOCK ML, WEI S-J et al.: Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J. Pharmacol. Exp. Ther. (2006) 319:44-52.
   PubMed Web of Science ®Google Scholar
• BLUTHE RM, KELLEY KW, DANTZER R: Effects of insulin-like growth factor-1 on cytokine-induced sickness behaviour in mice. Brain Behav. Immun. (2006) 20:57-63.
   PubMed Web of Science ®Google Scholar
• BRUSTOLIM D, RIBEIRO-DOS-SAMOS R, KAST RE, ALTSCHULER EL, SOARES MBP: A new chapter opens in inflammatory treatments: the antidepressant bupropion lowers production of TNF-a and interferon-γ in mice. Int. Immunopharmacol. (2006) 6:903-907.
   PubMed Web of Science ®Google Scholar
• NADJAR A, BLUTHE R-M, MAY MJ, DANTZER R, PARNET P: Inactivation of the cerebral NF-κB pathway inhibits interleukin-1β-induced sickness behaviour and c-Fos expression in various brain nuclei. Neuropsychopharmacology (2005) 30:1492-1499.
   PubMed Web of Science ®Google Scholar
• KIM Y-H, LEE S-H, LEE J-Y et al.: Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of NF-κB and c-Jun NH2-terminal kinase. Eur. J. Pharmacol. (2004) 494:1-9.
   PubMed Web of Science ®Google Scholar
• LIU H, LIU ZH, CHEN ZH, WANG JW, LI LS: Triplotide: a potent inhibitor of NF-κB in T-lymphocytes. Acta Pharmacol. Sin. (2000) 21:782-786.
   PubMed Web of Science ®Google Scholar
• ZHAO G, VASZAR LT, QIU D, SHI L, KAO PN: Anti-inflammatory effects of triplotide in human bronchial epithelial cells. Am. J. Physiol. (2000) 279:L958-L966.
   PubMed Web of Science ®Google Scholar
• VAN'T LAND B, BLIJLEVENS NMA, MARTEIJN J et al.: Role of curcumin and the inhibition of NF-κB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia (2004) 18:276-284.
   PubMed Web of Science ®Google Scholar
• BHARTI AC, DONATO N, SINGH S, AGGARWAL BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of NF-κB and IκBa kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood (2003) 101:1053-1062.
   PubMed Web of Science ®Google Scholar
• BREMNER P, HEINRICH M: Natural products as targeted modulators of the NF-κB pathway. J. Pharm. Pharmacol. (2002) 54:453-472.
   PubMed Web of Science ®Google Scholar
• AHN KS, SETHI G, SHISHODIA S et al.: Honokiol potentiates apoptosis, suppresses osteoclastogenesis and inhibits invasion through modulation of NF-κB activation pathway. Mol. Cancer Res. (2006) 4:621-633.
   PubMed Web of Science ®Google Scholar
• TSE AK, WAN CK, SHEN XL, YANG M, FONG WE: Honokiol inhibits TNF-a-stimulated NF-κB activation and NF-κB-regulated gene expression through suppression of IKK activation. Biochem. Pharmacol. (2005) 70:1443-1457.
   PubMed Web of Science ®Google Scholar
• NADJAR A, TRIDON V, MAY MJ et al.: NFκB activates In vivo the synthesis of inducible Cox-2 in the brain. J. Cereb. Blood Flow Met. (2005) 25:1047-1059.
   PubMed Web of Science ®Google Scholar
• SCHWARCZ R: The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. (2004) 4:12-17.
   PubMed Web of Science ®Google Scholar
• SAPKO MT, GUIDETTI P, YU P et al.: Endogenous kynurenine controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp. Neurol. (2006) 197:31-40.
   PubMed Web of Science ®Google Scholar
• PELLICCIARI R, RIZZO RC, CONSTANTINO G et al.: Modulators of kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulphonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem (2006) 1:528-531.
   PubMed Web of Science ®Google Scholar
• JIMI E, AOKI K, SAITO H et al.: Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. (2004) 10:617-624.
   PubMed Web of Science ®Google Scholar
• MALEMUD CJ: Small molecular weight inhibitors of stress-activated and mitogen-activated protein kinases. Mini Rev. Med. Chem. (2006) 6:689-698.
   PubMed Web of Science ®Google Scholar
• MALEMUD CJ: Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr. Opin. Pharmacol. (2007) 7:339-343.
   PubMed Web of Science ®Google Scholar
• NIELSEN DM: Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? Life Sci. (2005) 78:909-919.
   PubMed Web of Science ®Google Scholar
• ZUPANCIC M, GUILLEMINAULT C: Agomelatine: a preliminary review of a new antidepressant. CNS Drugs (2006) 20:981-992.
   PubMed Web of Science ®Google Scholar
• KUDLACZ E, PERRY B, SAWYER P et al.: The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. (2004) 4:51-57.
   PubMed Web of Science ®Google Scholar
• BATLIWALA FM, LI W, RITCHLIN CT et al.: Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol. Med. (2006) 11:21-29.
   Web of Science ®Google Scholar
• SHOU J, BULL CM, LI L et al.: Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat-collagen-induced arthritis model. Arthritis Res. Ther. (2006) R28:1-14.
   Google Scholar

Website

• http://www.docguide.com/news/content.nsf/news/852571020057CCF6852572FE006AA648 CP-690,550 (CP), an inhibitor of JAK3, provides significant improvements in remission rates over placebo for patients with moderate-to-severe active rheumatoid arthritis. Data presented at the Annual European Congress of Rheumatology (EULAR) Meeting in 2007. Abstr. SAT0040 (Accessed 18 June 2007)
   Google Scholar